Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 64980-632

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 64980-632). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg-30s.jpg (20mg 30s)

Label for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg strength, in a 30-capsule package. The label shows the Rising Pharmaceuticals logo, NDC 64980-632-03, and states the product is Rx only. It includes storage instructions, manufacturer CSPC Ouyi Pharmaceutical Co., Ltd., and distributor Rising Pharma Holdings, Inc.*

FDA Label Image

40mg-30s (40mg 30s)

The packaging label for Esomeprazole Magnesium Delayed-Release Capsules, USP 40 mg by Rising Pharmaceuticals. The front shows a blue and yellow design with the strength prominently in red, indicating 40 mg. The label states it contains 30 capsules and is Rx only. The manufacturer is CSPC Ouyi Pharmaceutical Co., Ltd, and the distributor is Rising Pharma Holdings, Inc. Storage instructions and issuance date (04/2024) are also included.*

FDA Label Image

Table-3 (Table 3)

This image shows a detailed drug interaction text panel for Esomeprazole magnesium. It covers clinical impacts and intervention recommendations related to various drugs and drug classes, including antiretrovirals, warfarin, methotrexate, CYP substrates, digoxin, clarithromycin with amoxicillin, drugs dependent on gastric pH for absorption, tacrolimus, neuroendocrine tumor investigations, secretion tests, and false positive urine tests for THC.*

FDA Label Image

Table-4 (Table 4)

A text panel discussing drug interaction warnings for esomeprazole magnesium related to CYP2C19 or CYP3A4 inducers and voriconazole. It includes clinical impact and intervention information for each interaction category, highlighting dose adjustments and concomitant use precautions.*

FDA Label Image

Esomeprazole-structure (Esomeprazole Structure)

Chemical structure of esomeprazole magnesium hydrate, showing two esomeprazole molecules coordinated with a magnesium ion and three water molecules.*

FDA Label Image

Esomeprazole-fig2 (Esomeprazole Fig2)

A line graph depicting the percentage maintained over six months for different dosages of Esomeprazole Magnesium (40 mg, 20 mg, 10 mg) compared to placebo. The x-axis represents time in months, and the y-axis shows the percent maintained. The 40 mg dose maintains the highest percentage over time, followed by 20 mg, 10 mg, and placebo with the lowest maintenance.*

FDA Label Image

Esomeprazole-fig3 (Esomeprazole Fig3)

A line graph depicting the percent maintained over six months for different treatments: Esomeprazole magnesium 40 mg, 20 mg, 10 mg, and placebo. The vertical axis shows percent maintained from 0 to 100, and the horizontal axis shows time in months from 0 to 6. Each treatment is represented by a distinct dashed or solid line with markers, illustrating changes over time.*

FDA Label Image

Esomeprazole-fig4 (Esomeprazole Fig4)

A line graph showing the percent of patients symptom-free over 28 diary days for Esomeprazole Magnesium 40 mg, 20 mg, and placebo groups. The y-axis represents percent of patients symptom-free from 0 to 100%, and the x-axis represents diary days from 0 to 28. Lines indicate increasing symptom-free percentages over time, with the 40 mg and 20 mg doses generally higher than placebo.*

FDA Label Image

Esomeprazole-fig5 (Esomeprazole Fig5)

A line graph showing the percentage of patients symptom-free over a 28-day period for Esomeprazole Magnesium 40 mg, 20 mg, and placebo groups. The y-axis represents the percent of patients symptom-free, ranging from 0 to 100%, and the x-axis shows the diary day from 0 to 28. The 20 mg and 40 mg doses show higher percentages of symptom-free patients compared to placebo throughout the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.